Debu Tripathy, MD, MD Anderson Cancer Center

Articles by Debu Tripathy, MD, MD Anderson Cancer Center

Updated Data for Metastatic HER2+ Breast Cancer

ByRuth O'Regan, MD, University of Rochester Medical Center,Joyce O'Shaugnessy, MD, Texas Oncology,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Debu Tripathy, MD, MD Anderson Cancer Center

January 25th 2021

Prognostic Tools for Early-Stage HER2+ Breast Cancer

ByRuth O'Regan, MD, University of Rochester Medical Center,Joyce O'Shaugnessy, MD, Texas Oncology,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Debu Tripathy, MD, MD Anderson Cancer Center

January 25th 2021

Current Treatment Landscape for HER2+ Breast Cancer

ByRuth O'Regan, MD, University of Rochester Medical Center,Joyce O'Shaugnessy, MD, Texas Oncology,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Debu Tripathy, MD, MD Anderson Cancer Center

January 25th 2021

Latest Updated Articles

Prognostic Tools for Early-Stage HER2+ Breast Cancer
January 25th 2021
Current Treatment Landscape for HER2+ Breast Cancer
January 25th 2021
Updated Data for Metastatic HER2+ Breast Cancer
January 25th 2021

Trending on OncLive

ASCO Guideline Update Broadens First-Line Treatment Options for HER2+ Gastroesophageal Cancer

CAR T-Cell Therapy Continues to Make Its Case in Early Relapsed Myeloma

FDA Awards Fast Track Designation to Safusidenib in IDH1-Mutant Glioma

pTVG-HP DNA Vaccine Extends Overall Survival vs Placebo in PSA-Recurrent Prostate Cancer

FDA Grants Breakthrough Therapy and Fast Track Status to 68Ga-NYM096 in ccRCC